Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

CAR T Cells in trials: Recent achievements and challenges that remain in the production of modified T cells for clinical applications

: Köhl, Ulrike; Arsenieva, Stanislava; Holzinger, Astrid; Abken, Hinrich


Human gene therapy 29 (2018), No.5, pp.559-568
ISSN: 1043-0342
ISSN: 1557-7422
Journal Article
Fraunhofer IZI ()
Bibliographie; ATMP; cancer; CAR; cell production; immunotherapy; T cells

The adoptive transfer of chimeric antigen receptor (CAR)-modified T cells is attracting growing interest for the treatment of malignant diseases. Early trials with anti-CD19 CAR T cells have achieved spectacular remissions in B-cell leukemia and lymphoma, so far refractory, very recently resulting in the Food and Drug Administration approval of CD19 CAR T cells for therapy. With further applications and increasing numbers of patients, the reproducible manufacture of high-quality clinical-grade CAR T cells is becoming an ever greater challenge. New processing techniques, quality-control mechanisms, and logistic developments are required to meet both medical needs and regulatory restrictions. This paper summarizes the state-of-the-art in manufacturing CAR T cells and the current challenges that need to be overcome to implement this type of cell therapy in the treatment of a variety of malignant diseases and in a greater number of patients.